000756 新华制药
交易中 07-15 10:17:57
资讯
新帖
简况
新华制药新提交4件商标注册申请
证券之星 · 07-13 20:59
新华制药新提交4件商标注册申请
新华制药:金泽百处于销售前准备阶段
证券之星 · 07-11
新华制药:金泽百处于销售前准备阶段
异动快报:新华制药(000756)7月11日11点4分触及涨停板
证券之星 · 07-11
异动快报:新华制药(000756)7月11日11点4分触及涨停板
新华制药新提交“率活力”等2件商标注册申请
证券之星 · 07-09
新华制药新提交“率活力”等2件商标注册申请
新华制药(000756.SZ)获得精氨酸布洛芬化学原料药上市申请批准
智通财经网 · 06-30
新华制药(000756.SZ)获得精氨酸布洛芬化学原料药上市申请批准
【新华制药:盐酸伊伐布雷定片获药品注册证书】新华制药公告,全资子公司山东淄博新达制药有限公司收到国家药品监督管理局核准签发的盐酸伊伐布雷定片《药品注册证书》。该药品适用于窦性心律且心率≥75次/分钟、伴有心脏收缩功能障碍的NYHAⅡ~Ⅳ级慢性心力衰竭患者,与标准治疗包括β-受体阻滞剂联合用药,或者用于禁忌或不能耐受β-受体阻滞剂治疗时。2024年中国城市公立医疗机构盐酸伊伐布雷定片销售额约3.5亿元。
金融界 · 06-30
【新华制药:盐酸伊伐布雷定片获药品注册证书】新华制药公告,全资子公司山东淄博新达制药有限公司收到国家药品监督管理局核准签发的盐酸伊伐布雷定片《药品注册证书》。该药品适用于窦性心律且心率≥75次/分钟、伴有心脏收缩功能障碍的NYHAⅡ~Ⅳ级慢性心力衰竭患者,与标准治疗包括β-受体阻滞剂联合用药,或者用于禁忌或不能耐受β-受体阻滞剂治疗时。2024年中国城市公立医疗机构盐酸伊伐布雷定片销售额约3.5亿元。
新华制药(000756.SZ):OAB-14干混悬剂完成Ⅱ期临床中国首例患者入组
智通财经 · 06-19
新华制药(000756.SZ):OAB-14干混悬剂完成Ⅱ期临床中国首例患者入组
新华制药:从药品批准上市到实现销售通常需要几个月时间进行准备
证券之星 · 06-19
新华制药:从药品批准上市到实现销售通常需要几个月时间进行准备
新华制药:治疗阿尔茨海默症的OAB-14干混悬剂属于创新药
证券之星 · 06-11
新华制药:治疗阿尔茨海默症的OAB-14干混悬剂属于创新药
新华制药:公司围绕多个方向开展研发工作包括创新药物和仿制药
证券之星 · 06-11
新华制药:公司围绕多个方向开展研发工作包括创新药物和仿制药
新华制药:公司生产经营情况正常
证券之星 · 06-06
新华制药:公司生产经营情况正常
新华制药(000756.SZ)取得二十碳五烯酸乙酯软胶囊药品注册证书
智通财经网 · 06-05
新华制药(000756.SZ)取得二十碳五烯酸乙酯软胶囊药品注册证书
新华制药(000756.SZ)取得注射用硫酸艾沙康唑药品注册证书
智通财经 · 06-05
新华制药(000756.SZ)取得注射用硫酸艾沙康唑药品注册证书
新华制药:公司围绕心脑血管类、解热镇痛类、消化系统类、抗代谢类、神经系统等方向开展研发工作
证券之星 · 06-04
新华制药:公司围绕心脑血管类、解热镇痛类、消化系统类、抗代谢类、神经系统等方向开展研发工作
新华制药:本公司属于A+H同时上市公司,公司始终心无旁骛做好主业,努力提升业绩,争取为股东创造更大价值
证券之星 · 05-28
新华制药:本公司属于A+H同时上市公司,公司始终心无旁骛做好主业,努力提升业绩,争取为股东创造更大价值
新华制药获得实用新型专利授权:“原料药清洗密闭输送装置”
证券之星 · 05-23
新华制药获得实用新型专利授权:“原料药清洗密闭输送装置”
新华制药获得发明专利授权:“sGC激动剂的合成方法”
证券之星 · 05-23
新华制药获得发明专利授权:“sGC激动剂的合成方法”
新华制药:公司与强生、罗氏、默克等200多家知名跨国企业建立长期战略合作关系
证券之星 · 05-23
新华制药:公司与强生、罗氏、默克等200多家知名跨国企业建立长期战略合作关系
新华制药:宠物饲料项目尚处于产能爬坡期
证券之星 · 05-23
新华制药:宠物饲料项目尚处于产能爬坡期
新华制药:公司围绕心脑血管类、解热镇痛类等方向开展研发工作
证券之星 · 05-23
新华制药:公司围绕心脑血管类、解热镇痛类等方向开展研发工作
加载更多
公司概况
公司名称:
山东新华制药股份有限公司
所属行业:
医药制造业
上市日期:
1997-08-06
主营业务:
山东新华制药股份有限公司的主营业务是原料药及中间体、化工产品销售。公司的主要产品是解热镇痛类原料药、片剂、针剂、胶囊剂、医药中间体。公司为国家级高新技术企业、国家火炬计划重点高新技术企业,国家综合性新药研发技术大平台(山东)产业化示范企业、山东省第二批创新型企业试点企业、山东省技术创新示范企业。
发行价格:
3.45
{"stockData":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":16.59,"timestamp":1752545877000,"preClose":17.01,"halted":0,"volume":12313450,"delay":0,"changeRate":-0.0247,"floatShares":493000000,"shares":690000000,"eps":0.6383,"marketStatus":"交易中","change":-0.42,"latestTime":"07-15 10:17:57","open":16.88,"high":16.98,"low":16.53,"amount":205000000,"amplitude":0.0265,"askPrice":16.59,"askSize":40,"bidPrice":16.58,"bidSize":40,"shortable":0,"etf":0,"ttmEps":0.6383,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1752550200000},"marketStatusCode":2,"adr":0,"adjPreClose":17.01,"symbolType":"stock","openAndCloseTimeList":[[1752543000000,1752550200000],[1752555600000,1752562800000]],"highLimit":18.71,"lowLimit":15.31,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":689776535,"isCdr":false,"pbRate":2.28,"roa":"--","peRate":25.990913,"roe":"2.21%","epsLYR":0.69,"committee":0.052534,"marketValue":11443000000,"turnoverRate":0.025,"status":1,"hkstockBrief":{"symbol":"00719","market":"HK","secType":"STK","nameCN":"山东新华制药股份","latestPrice":8.3,"timestamp":1752545878066,"preClose":8.44,"halted":0,"volume":5140000,"delay":0,"premium":"-54.31"},"floatMarketCap":8173000000},"requestUrl":"/m/hq/s/000756","defaultTab":"news","newsList":[{"id":"2551923319","title":"新华制药新提交4件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2551923319","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551923319?lang=zh_cn&edition=full","pubTime":"2025-07-14 04:59","pubTimestamp":1752440361,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示,近日山东新华制药股份有限公司新提交4件商标注册申请。商标申请详情如下:今年以来山东新华制药股份有限公司新申请注册商标15件,截止目前公司共持有注册商标753件,另有79件商标尚在注册申请中。通过天眼查大数据分析,山东新华制药股份有限公司共对外投资了19家企业,参与招投标项目13783次;财产线索方面有商标信息556条,专利信息521条;此外企业还拥有行政许可855个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071400001148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2550987491","title":"新华制药:金泽百处于销售前准备阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2550987491","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550987491?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:32","pubTimestamp":1752222734,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)07月11日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司获批上市的二十碳五烯酸乙酯开始销售了吗?商品名叫什么?新华制药回复:您好!从药品批准上市到实现销售,通常需要几个月时间进行准备。公司二十碳五烯酸乙脂软胶囊商品名叫“金泽百”,处于销售前准备阶段。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071100026076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2550019856","title":"异动快报:新华制药(000756)7月11日11点4分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2550019856","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550019856?lang=zh_cn&edition=full","pubTime":"2025-07-11 11:05","pubTimestamp":1752203120,"startTime":"0","endTime":"0","summary":"证券之星7月11日盘中消息,11点4分新华制药触及涨停板。目前价格17.67,上涨10.02%。其所属行业化学制药目前上涨。领涨股为常山药业。该股为创新药,阿尔茨海默病,化学原料药概念热股,当日创新药概念上涨1.42%,阿尔茨海默病概念上涨1.12%,化学原料药概念上涨1.02%。7月10日的资金流向数据方面,主力资金净流入1163.33万元,占总成交额3.54%,游资资金净流出644.94万元,占总成交额1.96%,散户资金净流出518.39万元,占总成交额1.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071100013021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2550665948","title":"新华制药新提交“率活力”等2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2550665948","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550665948?lang=zh_cn&edition=full","pubTime":"2025-07-10 05:07","pubTimestamp":1752095278,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示,近日山东新华制药股份有限公司新提交“率活力”等2件商标注册申请。商标申请详情如下:今年以来山东新华制药股份有限公司新申请注册商标11件,截止目前公司共持有注册商标753件,另有75件商标尚在注册申请中。通过天眼查大数据分析,山东新华制药股份有限公司共对外投资了19家企业,参与招投标项目13776次;财产线索方面有商标信息556条,专利信息520条;此外企业还拥有行政许可855个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000003393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2547060069","title":"新华制药(000756.SZ)获得精氨酸布洛芬化学原料药上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2547060069","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547060069?lang=zh_cn&edition=full","pubTime":"2025-06-30 17:12","pubTimestamp":1751274769,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药(000756.SZ)发布公告,近日,公司收到国家药品监督管理局核准签发的精氨酸布洛芬《化学原料药上市申请批准通知书》。精氨酸布洛芬主要用于牙痛、痛经、因创伤引起的疼痛(例如:运动性损伤)、关节和韧带痛、背痛、头痛、神经痛以及流感引起的发热。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1311793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新华制药(000756.SZ)获得精氨酸布洛芬化学原料药上市申请批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2547061838","title":"【新华制药:盐酸伊伐布雷定片获药品注册证书】新华制药公告,全资子公司山东淄博新达制药有限公司收到国家药品监督管理局核准签发的盐酸伊伐布雷定片《药品注册证书》。该药品适用于窦性心律且心率≥75次/分钟、伴有心脏收缩功能障碍的NYHAⅡ~Ⅳ级慢性心力衰竭患者,与标准治疗包括β-受体阻滞剂联合用药,或者用于禁忌或不能耐受β-受体阻滞剂治疗时。2024年中国城市公立医疗机构盐酸伊伐布雷定片销售额约3.5亿元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2547061838","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547061838?lang=zh_cn&edition=full","pubTime":"2025-06-30 17:10","pubTimestamp":1751274638,"startTime":"0","endTime":"0","summary":"新华制药公告,全资子公司山东淄博新达制药有限公司收到国家药品监督管理局核准签发的盐酸伊伐布雷定片《药品注册证书》。该药品适用于窦性心律且心率≥75次/分钟、伴有心脏收缩功能障碍的NYHAⅡ~Ⅳ级慢性心力衰竭患者,与标准治疗包括β-受体阻滞剂联合用药,或者用于禁忌或不能耐受β-受体阻滞剂治疗时。2024年中国城市公立医疗机构盐酸伊伐布雷定片销售额约3.5亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/30171051387818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["000756","BK1574","01477","BK0164","BK1191","BK0239"],"gpt_icon":0},{"id":"2544915684","title":"新华制药(000756.SZ):OAB-14干混悬剂完成Ⅱ期临床中国首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2544915684","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544915684?lang=zh_cn&edition=full","pubTime":"2025-06-19 16:17","pubTimestamp":1750321031,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药(000756.SZ)公告,公司治疗轻至中度阿尔兹海默病的OAB-14干混悬剂完成Ⅱ期临床中国首例患者入组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1307207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新华制药(000756.SZ):OAB-14干混悬剂完成Ⅱ期临床中国首例患者入组","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0164","000756"],"gpt_icon":0},{"id":"2544153150","title":"新华制药:从药品批准上市到实现销售通常需要几个月时间进行准备","url":"https://stock-news.laohu8.com/highlight/detail?id=2544153150","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544153150?lang=zh_cn&edition=full","pubTime":"2025-06-19 15:37","pubTimestamp":1750318675,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)06月19日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司新药“二十碳五烯酸乙脂软胶囊”,在哪些城市的医院里有配,我想去配。新华制药回复:您好!从药品批准上市到实现销售,通常需要几个月时间进行准备。公司二十碳五烯酸乙脂软胶囊处于销售前准备阶段。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061900017273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0164","000756"],"gpt_icon":0},{"id":"2542059383","title":"新华制药:治疗阿尔茨海默症的OAB-14干混悬剂属于创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2542059383","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542059383?lang=zh_cn&edition=full","pubTime":"2025-06-11 16:15","pubTimestamp":1749629722,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘,您好!新华制药研发的治疗阿尔茨海默病的OAB-14干混悬剂是否属于创新药?现在进行到什么程度了,审批上市没有?谢谢!新华制药回复:您好!治疗阿尔茨海默症的OAB-14干混悬剂属于创新药,目前处于二期临床前准备过程中。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061100023134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","06978","000756","159992","BK1574","BK0164","BK0239"],"gpt_icon":0},{"id":"2542055403","title":"新华制药:公司围绕多个方向开展研发工作包括创新药物和仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2542055403","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542055403?lang=zh_cn&edition=full","pubTime":"2025-06-11 16:09","pubTimestamp":1749629361,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药06月11日在投资者关系平台上答复投资者关心的问题。公司围绕心脑血管类、解热镇痛类、消化系统类、抗代谢类、神经系统、精麻药品等方向开展研发工作,包括创新药物和仿制药。进入研发管线的药物有100多个。在创新药领域已构建多个大研发平台,在研产品包括OAB14等多个1类创新药物进展顺利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061100022501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","BK1574","000756","06978","BK0239","BK0164"],"gpt_icon":0},{"id":"2541889001","title":"新华制药:公司生产经营情况正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2541889001","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541889001?lang=zh_cn&edition=full","pubTime":"2025-06-06 11:34","pubTimestamp":1749180847,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)06月06日在投资者关系平台上答复投资者关心的问题。投资者提问:好多医药股涨势喜人,但贵股没有起色,贵公司营业是否正常,有潜在的利空,甚至退市的风险吗?新华制药回复:您好,公司生产经营情况正常,公司始终心无旁骛做好主业,努力提升业绩,争取为投资者创造更大价值。 股价变化受到多重因素影响,如市场竞争激烈、 行业政策、 市场情绪与预期等。感谢您对公司关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060600012805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2541021417","title":"新华制药(000756.SZ)取得二十碳五烯酸乙酯软胶囊药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2541021417","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541021417?lang=zh_cn&edition=full","pubTime":"2025-06-05 17:54","pubTimestamp":1749117240,"startTime":"0","endTime":"0","summary":"新华制药(000756.SZ)公告,公司收到国家药品监督管理局核准签发的二十碳五烯酸乙酯软胶囊《药品注册证书》。在控制饮食的基础上,本品用于降低重度高甘油三酯血症(≥500mg/dL)成年患者的甘油三酯水平。与他汀类药物联合使用,用于确诊心血管疾病或糖尿病伴≥2种其他心血管疾病危险因素,合并高甘油三酯血症(≥150mg/dL)的成年患者,以降低心血管事件风险。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-06-05/doc-ineyznmf6347036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2541026018","title":"新华制药(000756.SZ)取得注射用硫酸艾沙康唑药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2541026018","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541026018?lang=zh_cn&edition=full","pubTime":"2025-06-05 17:51","pubTimestamp":1749117113,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药(000756.SZ)公告,公司收到国家药品监督管理局核准签发的注射用硫酸艾沙康唑《药品注册证书》。注射用硫酸艾沙康唑适用于治疗成人患者下列感染:侵袭性曲霉病;侵袭性毛霉病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1301769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新华制药(000756.SZ)取得注射用硫酸艾沙康唑药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2540080624","title":"新华制药:公司围绕心脑血管类、解热镇痛类、消化系统类、抗代谢类、神经系统等方向开展研发工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2540080624","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540080624?lang=zh_cn&edition=full","pubTime":"2025-06-04 11:34","pubTimestamp":1749008047,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司在创新药方面,有何业务发展或布局?新华制药回复:您好!公司围绕心脑血管类、解热镇痛类、消化系统类、抗代谢类、神经系统等方向开展研发工作,包括创新药物和仿制药。巨潮资讯网为公司指定信息披露媒体,请以公司公告为准。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060400012899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2538423670","title":"新华制药:本公司属于A+H同时上市公司,公司始终心无旁骛做好主业,努力提升业绩,争取为股东创造更大价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2538423670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538423670?lang=zh_cn&edition=full","pubTime":"2025-05-28 16:42","pubTimestamp":1748421732,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)05月28日在投资者关系平台上答复投资者关心的问题。投资者提问:若过去12个月日均市值持续低于40亿港元(沪港通和深港通统一标准),则可能H股山东新华制药股份被调出港股通,建议贵公司取消分红改回购新华制药回复:您好!本公司属于A+H同时上市公司,公司始终心无旁骛做好主业,努力提升业绩,争取为股东创造更大价值。根据《深圳证券交易所深港通业务实施办法(2023年修订)》,公司不存在您所担心情形。感谢您的意见与建议。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052800025420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2537151163","title":"新华制药获得实用新型专利授权:“原料药清洗密闭输送装置”","url":"https://stock-news.laohu8.com/highlight/detail?id=2537151163","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537151163?lang=zh_cn&edition=full","pubTime":"2025-05-24 03:16","pubTimestamp":1748027782,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示新华制药新获得一项实用新型专利授权,专利名为“原料药清洗密闭输送装置”,专利申请号为CN202520427299.2,授权日为2025年5月23日。本装置能够实现原料药与清洗水的高效分离,延长设备使用寿命,同时抑制粉尘扩散,确保原料药纯度。今年以来新华制药新获得专利授权17个,较去年同期增加了21.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052400006882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2537151193","title":"新华制药获得发明专利授权:“sGC激动剂的合成方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2537151193","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537151193?lang=zh_cn&edition=full","pubTime":"2025-05-24 03:16","pubTimestamp":1748027766,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示新华制药新获得一项发明专利授权,专利名为“sGC激动剂的合成方法”,专利申请号为CN202411703298.2,授权日为2025年5月23日。今年以来新华制药新获得专利授权17个,较去年同期增加了21.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052400006810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2537890776","title":"新华制药:公司与强生、罗氏、默克等200多家知名跨国企业建立长期战略合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2537890776","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537890776?lang=zh_cn&edition=full","pubTime":"2025-05-23 15:30","pubTimestamp":1747985452,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)05月23日在投资者关系平台上答复投资者关心的问题。投资者提问:还想问新华制药和国际巨头 例如 强生(Johnson & Johnson),罗氏(Roche)默沙东(Merck & Co.)辉瑞(Pfizer)艾伯维(AbbVie)有没有合作?新华制药回复:您好!公司作为全球解热镇痛类药物重要生产企业,与可乐、三菱、葛兰素史克、拜耳、强生、罗氏、默克等200多家知名跨国企业建立了长期战略合作关系。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052300018387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2537907714","title":"新华制药:宠物饲料项目尚处于产能爬坡期","url":"https://stock-news.laohu8.com/highlight/detail?id=2537907714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537907714?lang=zh_cn&edition=full","pubTime":"2025-05-23 15:30","pubTimestamp":1747985449,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)05月23日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司,宠物饲料品质如何?宠物原料药品研发进度如何?宠物饲料进入产能爬坡期了吗?新华制药回复:您好!新华制药是全球解热镇痛类药物重要生产企业,有严格质量管控体系,宠物饲料项目尚处于产能爬坡期。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052300018382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0164","000756"],"gpt_icon":0},{"id":"2537907244","title":"新华制药:公司围绕心脑血管类、解热镇痛类等方向开展研发工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2537907244","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537907244?lang=zh_cn&edition=full","pubTime":"2025-05-23 15:30","pubTimestamp":1747985449,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)05月23日在投资者关系平台上答复投资者关心的问题。投资者提问:研发管线中是否新增辅助生殖药物?新华制药回复:您好!公司围绕心脑血管类、解热镇痛类、消化系统类、抗代谢类、神经系统等方向开展研发工作,包括创新药物和仿制药。进入研发管线的药物有100多个。在创新药领域已构建多个大研发平台(如新型给药系统、小分子创新等),在研产品包括OAB-14(用于阿尔茨海默病治疗)等多个1类创新药物进展顺利。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052300018384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK0164"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752545880740,"stockEarnings":[{"period":"1week","weight":0.0436},{"period":"1month","weight":0.1074},{"period":"3month","weight":0.1996},{"period":"6month","weight":0.1103},{"period":"1year","weight":0.1796},{"period":"ytd","weight":0.0827}],"compareEarnings":[{"period":"1week","weight":0.0134},{"period":"1month","weight":0.0422},{"period":"3month","weight":0.0771},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1846},{"period":"ytd","weight":0.0501}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东新华制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1997-08-06","address":"山东省淄博市张店区高新技术产业开发区化工区","registeredCapital":"68977万元","survey":" 山东新华制药股份有限公司的主营业务是原料药及中间体、化工产品销售。公司的主要产品是解热镇痛类原料药、片剂、针剂、胶囊剂、医药中间体。公司为国家级高新技术企业、国家火炬计划重点高新技术企业,国家综合性新药研发技术大平台(山东)产业化示范企业、山东省第二批创新型企业试点企业、山东省技术创新示范企业。","listedPrice":3.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新华制药,000756,新华制药股票,新华制药股票老虎,新华制药股票老虎国际,新华制药行情,新华制药股票行情,新华制药股价,新华制药股市,新华制药股票价格,新华制药股票交易,新华制药股票购买,新华制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}